To hear about similar clinical trials, please enter your email below
Trial Title:
MVX-ONCO-1 in Patients With Solid Tumor
NCT ID:
NCT02193503
Condition:
Solid Tumor
Cancer
Conditions: Official terms:
Neoplasms
Conditions: Keywords:
cancer
solid tumors
gene therapy
cell therapy
encapsulation
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Active, not recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Other
Intervention name:
Treatment
Description:
Treatment is the implantation of loaded capsules + injection of irradiated autologous
tumor cells
Arm group label:
treatment
Other name:
- capsules MVX-1-loaded (medical device)
Other name:
- irradiated autologous tumor cells (cell therapy)
Summary:
The objectives are to assess the safety and tolerability of 6 vaccine doses of
MVX-ONCO-1, administered sub-cutaneously (injections and capsules implantations), in
patients with advanced metastatic solid tumor in progression who are not or not any
longer amenable to any standard therapy of their tumour disease.
Detailed description:
Endpoints:
Primary: To assess safety parameters including adverse and serious adverse events
(incidence, causality, severity), local and systemic tolerance to the administered study
treatment, changes in laboratory values and vital signs in patients with solid tumor;
Secondary: to measure some tumor responses in using imaging technique, serological tumor
markers, immune monitoring and metabolic monitoring.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Male or female patients aged 18 years and older with advanced metastatic cancer in
progression of various sites [Carcinoma of lung (either small cell or non-small
cell), colon, breast, pancreas (exocrine or endocrine), stomach, oesophagus,
head&neck, thyroid, kidney, bladder, prostate, ovary, uterus (cervix or corpus);
Sarcoma of soft tissue, bone, uterus, melanoma; primary brain tumor] where all
recognized treatment are exhausted or not feasible.
- Life expectancy: estimate of at least 4 months.
Exclusion Criteria:
- Have participated in any other investigational study or received an experimental
therapeutic procedure considered to interfere with the study in the 4 preceding
weeks.
- Have received any chemotherapy treatment in the 4 preceding weeks.
- Serious concomitant health condition such as organ transplant requiring
immunosuppressive drugs, severe psychiatric disorders.
- History of second cancer within the last 2 years with the exception of basal cell
carcinoma of skin and localized cervical carcinoma treated with curative intent.
- Patient with a systemic disease other than cancer, that is not controlled by usual
medication.
- Therapeutic anticoagulation with coumarine or continues iv heparin. Low-molecular
weight heparin (LMWH) is permitted as long as treatment can be withheld several
hours prior to subcutaneous implantation.
- Positive HIV-1, HIV-2, HTLV-1, HTLV-2, hepatitis B surface antigen, or hepatitis C
antibody.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Hopitaux Universitaires de Genève - HUG
Address:
City:
Geneva
Zip:
1205
Country:
Switzerland
Start date:
March 2014
Completion date:
December 2026
Lead sponsor:
Agency:
Maxivax SA
Agency class:
Industry
Source:
Maxivax SA
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT02193503